Effect of Bevacizumab in advanced low grade serous ovarian cancer
Connect2Clinic
An end-to-end Practice Management Platform that makes your In-Clinic & Online practice seamless!
The study was to explore the efficacy of Bevacizumab (Bev) on survival outcomes in advanced low-grade serous ovarian cancer (LGSOC) both in the first line and in the recurrent setting. The results suggested that Bev was effective in LGSOC both at diagnosis and at the time of relapse.